Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.
National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan.
PLoS One. 2021 Feb 3;16(2):e0245762. doi: 10.1371/journal.pone.0245762. eCollection 2021.
BACKGROUND: The term "metabolic (dysfunction)-associated fatty liver disease" (MAFLD) is suggested alternative for "non-alcoholic fatty liver disease" (NAFLD), as it better reflects metabolic dysfunction. No study has compared outcomes of the two diagnostic criteria. METHODS: In an ongoing, community-based, cohort-study in suburban Sri Lanka, participants were randomly selected in 2007. They were reassessed in 2014 to evaluate new-onset metabolic traits (MTs) and cardiovascular-events (CVEs). Baseline characteristics, MTs and CVEs after 7-years were compared in NAFLD and MAFLD and vs. controls. Similarly, we compared these parameters in those excluded by the NAFLD definition but captured by the MAFLD definition and vice versa, and vs. controls. FINDINGS: Of 2985 recruited in 2007, 940 (31.5%) had NAFLD, 990 (33.1%) had MAFLD and 362 (12.1%) were controls. When compared to NAFLD, MAFLD captured an additional 2.9% and lost 1.3% individuals. At baseline, anthropometric and metabolic traits were similar in NAFLD and MAFLD. At follow-up in 7-years, the risk of having new-onset MTs and fatal/non-fatal CVEs were similar in the groups, but were significantly higher compared to controls. Those excluded by the NAFLD definition but captured by the MAFLD definition showed higher baseline MTs compared to those excluded by the MAFLD definition but captured by the NAFLD definition, and had substantially higher risk for having new-onset MTs and CVEs compared to controls. INTERPRETATION: Although NAFLD and MAFLD had similar MTs at baseline, and similar outcomes after 7-years, those who were excluded by the NAFLD definition but captured by the MAFLD definition seem at higher risk of adverse outcomes than those excluded by the MAFLD definition but captured by the NAFLD definition. Although the increase in the index population was small, redefining NAFLD as MAFLD seemed to improve clinical utility.
背景:代谢相关脂肪性肝病(MAFLD)这一术语是对非酒精性脂肪性肝病(NAFLD)的替代,因为它更好地反映了代谢功能障碍。目前尚无研究比较这两种诊断标准的结果。
方法:本研究为正在进行的、基于社区的斯里兰卡郊区队列研究,于 2007 年随机选择参与者。2014 年对他们进行了重新评估,以评估新出现的代谢特征(MTs)和心血管事件(CVE)。比较了基线特征、7 年后的 MTs 和 CVE 在 NAFLD 和 MAFLD 患者与对照组之间的差异。同样,我们比较了那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者与对照组之间的差异,反之亦然。
结果:在 2007 年招募的 2985 名患者中,940 名(31.5%)患有 NAFLD,990 名(33.1%)患有 MAFLD,362 名(12.1%)为对照组。与 NAFLD 相比,MAFLD 多捕捉了 2.9%的患者,少捕捉了 1.3%的患者。在基线时,NAFLD 和 MAFLD 患者的人体测量学和代谢特征相似。在 7 年的随访中,新发生 MTs 和致命/非致命 CVE 的风险在各组中相似,但明显高于对照组。那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者,其基线 MTs 高于那些被 MAFLD 定义排除但被 NAFLD 定义捕获的患者,与对照组相比,新发生 MTs 和 CVE 的风险显著更高。
解释:虽然 NAFLD 和 MAFLD 在基线时的 MTs 相似,且 7 年后的结果相似,但那些被 NAFLD 定义排除但被 MAFLD 定义捕获的患者的不良结局风险似乎高于那些被 MAFLD 定义排除但被 NAFLD 定义捕获的患者。尽管纳入人群的增加很小,但将 NAFLD 重新定义为 MAFLD 似乎提高了临床实用性。
World J Gastroenterol. 2023-1-21
J Gastroenterol Hepatol. 2022-2
Cardiovasc Diabetol. 2022-12-3
Int J Environ Res Public Health. 2021-8-26
Clin Gastroenterol Hepatol. 2021-10
J Multidiscip Healthc. 2025-7-29
Rev Cardiovasc Med. 2023-5-31
J Cachexia Sarcopenia Muscle. 2024-10
Hepatology. 2021-3
Liver Int. 2020-9
Liver Int. 2020-6
Int J Environ Res Public Health. 2020-3-11
Gastroenterology. 2020-5
Gastroenterology. 2020-5
Medicine (Baltimore). 2018-3
Nat Rev Gastroenterol Hepatol. 2017-9-20